AstraZeneca's Enhertu Wins China Reimbursement

AstraZeneca's Enhertu included in China's state insurance reimbursement
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an update from the National Healthcare Security Administration. The antibody-drug conjugate,
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move that will boost the British drugmaker’s sales in the country in the midst of an ongoing probe that’s ensnared some of its senior executives.
AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe
AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY), would be added for reimbursement by state-run medical insurance in China,
Addition of AstraZeneca breast cancer drug Enhertu to China state insurance list
China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance scheme from January 1, as per a recent update from the National
AstraZeneca's Enhertu breast cancer drug added to China's state insurance list
AstraZeneca's blockbuster breast cancer drug Enhertu will be added to China's state-run health insurance scheme from Jan. 1, according to an update from the National Healthcare Security Administration.
pharmaphorum14h
Kelun's MSD-partnered TROP2 drug gets first okay in China
which was cleared in China for TNBC in 2022. The approval means Kelun has brought its TROP2 ADC to market ahead of ...
STAT23d
AstraZeneca says China has detained a senior executive
The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after ...
Wall Street Journal2d
AstraZeneca Stock Falls on China Probe Fears
AstraZeneca said last week that its China chief, Leon Wang, was under investigation by authorities there, raising concerns about the stability of the company’s sales in the country, its second ...
AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades
AstraZeneca Plc’s recent share-price rout has gone so far that the pharma stock has shaken off the last of its bearish ...
AstraZeneca Names A MSK Leader To Global Cancer Post
Dr. Bob Li, a top Asian leader from the New York-based Memorial Sloan Kettering Cancer Center, has become global head of ...
HUTCHMED Announces Renewal Of ORPATHYS Inclusion In China's NRDL
(RTTNews) - HUTCHMED (China) Limited (?HCM) announced that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug ...